GWM
NURO

Geneos Wealth Management’s NeuroMetrix, Inc. Common Stock NURO Stock Holding History

Geneos Wealth Management’s Portfolio NURO Stock Details NURO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25
Closed – – 2670
2022
Q2 		$0 Hold
25
– – ﹤0.01% 2827
2022
Q1 		$0 Sell
25
-1
-4% -$36 ﹤0.01% 3029
2021
Q4 		$1K Buy
+26
New +$1.54K ﹤0.01% 2738

Other funds holding NURO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geneos Wealth Management's NURO Position: Q3 2022 in Review

Geneos Wealth Management sold out of NeuroMetrix, Inc. Common Stock (NURO) in Q3 2022, closing a stake of 25 shares.

Geneos Wealth Management first reported a position in NURO in Q4 2021 and held it in 3 quarters. The position peaked at $1K in Q4 2021. 16 funds tracked by Wall St. Rank hold NURO as of Q3 2022.

  • Geneos Wealth Management reported no remaining NeuroMetrix, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 25 NeuroMetrix, Inc. Common Stock shares in Q3 2022.
  • Geneos Wealth Management first reported a position in NeuroMetrix, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Geneos Wealth Management's NeuroMetrix, Inc. Common Stock position peaked at $1K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held NeuroMetrix, Inc. Common Stock as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.